EPS for Theratechnologies Inc. (TH) Expected At $-0.05

March 15, 2018 - By Louis Casey

 EPS for Theratechnologies Inc. (TH) Expected At $ 0.05

Analysts expect Theratechnologies Inc. (TSE:TH) to report $-0.05 EPS on April, 5.They anticipate $0.02 EPS change or 66.67 % from last quarter’s $-0.03 EPS. After having $-0.06 EPS previously, Theratechnologies Inc.’s analysts see -16.67 % EPS growth. The stock increased 0.81% or $0.08 during the last trading session, reaching $9.94. About 266,014 shares traded or 80.46% up from the average. Theratechnologies Inc. (TSE:TH) has 0.00% since March 15, 2017 and is . It has underperformed by 16.70% the S&P500.

Theratechnologies Inc. (TSE:TH) Ratings Coverage

Among 2 analysts covering Theratechnologies Inc. (TSE:TH), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Theratechnologies Inc. had 6 analyst reports since February 25, 2016 according to SRatingsIntel. National Bank Canada downgraded the stock to “Outperform” rating in Friday, November 11 report.

Theratechnologies Inc., specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and an enhanced life among HIV patients. The company has market cap of $745.27 million. The Company’s lead product is EGRIFTA, which increases the incidence or progression of diabetic retinopathy in diabetic HIV-infected patients with lipodystrophy and excess abdominal fat in the United States and Canada. It currently has negative earnings.

More notable recent Theratechnologies Inc. (TSE:TH) news were published by: Prnewswire.com which released: “Theratechnologies Announces Results from the Last Pivotal Phase III Trial of …” on November 10, 2016, also Prnewswire.com with their article: “Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo …” published on March 06, 2018, Marketwired.com published: “Theratechnologies Announces Decision by the FDA to Extend the Ibalizumab …” on November 14, 2017. More interesting news about Theratechnologies Inc. (TSE:TH) were released by: Bioworld.com and their article: “Theratechnologies, Taimed get FDA nod, and several firsts, for HIV drug” published on March 08, 2018 as well as Marketwired.com‘s news article titled: “Theratechnologies Announces Financial Results for Second Quarter of 2017” with publication date: July 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: